Oncological Outcome After Laparoscopic 'No-touch' RAMPS


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 15 08 2023
revised: 14 09 2023
accepted: 19 09 2023
medline: 2 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

The validity of laparoscopic distal pancreatectomy in left-sided pancreatic adenocarcinoma (PDAC) is still unclear. However, a meticulous surgical dissection through a "no-touch" technique might allow a radical oncological resection with minimal risk of tumor dissemination and seeding. This study aimed to evaluate the oncological outcomes of the laparoscopic "no touch" technique versus the "touch" technique. From 2001 to 2020, we retrospectively analyzed 45 patients undergoing laparoscopic distal pancreatectomy (LDP) for PDAC in two centers. Factors associated with overall (OS), disease-free survival (DFS) and time to recurrence (TTR) were identified. The OS rates in the 'no-touch' and 'touch' groups were 95% vs. 78% (1-year OS); 50% vs. 50% (3-year OS), respectively (p=0.60). The DFS rates in the 'no-touch' and 'touch' groups were 72 % vs. 57% (1-year DFS); 32% vs. 28% (3-year DFS), respectively (p=0.11). The TTR rates in the 'no-touch' and 'touch' groups were 77% vs. 61% (1-year TTR); 54% vs. 30% (3-year TTR); 46% vs. 11% (5-year TTR); respectively (p=0.02) In multivariate analysis the only factors were Touch technique [odds ratio (OR)=2.62, p=0.02] and lymphovascular emboli (OR=4.8; p=0.002). We advise the 'no-touch' technique in patients with resectable PDAC in the pancreatic body and tail. Although this study does not provide definitive proof of superiority, no apparent downsides are present for the 'no-touch' technique in this setting although there could be oncological benefits.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The validity of laparoscopic distal pancreatectomy in left-sided pancreatic adenocarcinoma (PDAC) is still unclear. However, a meticulous surgical dissection through a "no-touch" technique might allow a radical oncological resection with minimal risk of tumor dissemination and seeding. This study aimed to evaluate the oncological outcomes of the laparoscopic "no touch" technique versus the "touch" technique.
PATIENTS AND METHODS METHODS
From 2001 to 2020, we retrospectively analyzed 45 patients undergoing laparoscopic distal pancreatectomy (LDP) for PDAC in two centers. Factors associated with overall (OS), disease-free survival (DFS) and time to recurrence (TTR) were identified.
RESULTS RESULTS
The OS rates in the 'no-touch' and 'touch' groups were 95% vs. 78% (1-year OS); 50% vs. 50% (3-year OS), respectively (p=0.60). The DFS rates in the 'no-touch' and 'touch' groups were 72 % vs. 57% (1-year DFS); 32% vs. 28% (3-year DFS), respectively (p=0.11). The TTR rates in the 'no-touch' and 'touch' groups were 77% vs. 61% (1-year TTR); 54% vs. 30% (3-year TTR); 46% vs. 11% (5-year TTR); respectively (p=0.02) In multivariate analysis the only factors were Touch technique [odds ratio (OR)=2.62, p=0.02] and lymphovascular emboli (OR=4.8; p=0.002).
CONCLUSION CONCLUSIONS
We advise the 'no-touch' technique in patients with resectable PDAC in the pancreatic body and tail. Although this study does not provide definitive proof of superiority, no apparent downsides are present for the 'no-touch' technique in this setting although there could be oncological benefits.

Identifiants

pubmed: 37909963
pii: 43/11/4983
doi: 10.21873/anticanres.16697
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4983-4991

Informations de copyright

Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Alessandro D Mazzotta (AD)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France; alex.mazzotta@gmail.com.

Eduard A VAN Bodegraven (EA)

Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Niccolo Petrucciani (N)

Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, St Andrea Hospital, Sapienza University, Rome, Italy.

Sofia Usai (S)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Adriano Costa Carneiro (AC)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Ecoline Tribillon (E)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Jean Marc Ferraz (JM)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Olivier R Busch (OR)

Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Brice Gayet (B)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Marc G Besselink (MG)

Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Olivier Soubrane (O)

Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH